Open an account

Voyager Therapeutics

VYGR · NASDAQ

$2.19+$0.14 (+6.83%)TodayMarket closed ·
Prev close $2.05

VYGR analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy1
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 11 analysts

Average $15.19 (+593.5% upside)

Low
$8.08
Now
$2.19
High
$26.25

Upgrades and downgrades

The latest rating actions, newest first

VYGR analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Aug 10, 2026MaintainsBuy
HC Wainwright & Co.Mar 17, 2026MaintainsBuy
HC Wainwright & Co.Nov 12, 2025MaintainsBuy

The case for and against

Updated Feb 9, 2026

Bull case

Voyager Therapeutics Inc. is strategically positioned for growth through its innovative TRACER platform, which is anticipated to generate revenues from collaborations progressing toward clinical trials in the 2030s. The company has demonstrated promising preclinical results, such as VY1706's ability to significantly reduce tau messenger RNA and protein levels while ensuring lower liver exposure compared to traditional AAV9 approaches, suggesting enhanced efficacy and safety. Additionally, the recent advancements in non-viral delivery methods indicate a competitive edge in sustaining central nervous system exposure, reinforcing the potential for durable clinical benefits in treating severe neurological diseases.

Bear case

Voyager Therapeutics Inc. has faced significant challenges in advancing its gene therapy programs, leading to concerns about the viability of its pipeline and the potential for long-term profitability. The company's investment in AAV-based therapies has been met with setbacks, highlighting issues related to clinical trial outcomes and the competitive landscape in the gene therapy market. Additionally, financial data indicates rising operational costs and a need for substantial funding, which may dilute existing shareholder value and contribute to a negative perception regarding the stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.